Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection

Study Overview
=================
Brief Summary
-----------------
National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiving a medical treatment for the underlying cancer

Official Title
-----------------
Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection

Conditions
-----------------
Sars-CoV2, Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: I1. Confirmed diagnosis of any type of solid or hematologic tumor; I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ; I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (>38°C) and/or respiratory tract symptoms), either confirmed or not. Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ; I4. Patient and/or family did not decline data collection after complete information.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality of cancer patients under active anticancer treatment | Mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative). | 28 days after the date of the diagnostic procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival will be defined as the time from the date of the first diagnostic procedure (either diagnostic test or chest imaging) to the date of death due to any cause. | 6 months (i.e. at the the time of last patient last visit) | 
| Hospitalizations | The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients) | 28 days after the date of the diagnostic procedure | 
| Death | Cause of death, related or not to the COVID-19 | 6 months (i.e. at the the time of last patient last visit) | 
| Complications | Associated complications described by their type | 28 days after the date of the diagnostic procedure | 
| Hospitalizations | proportion of hospitalizations | 28 days after the date of the diagnostic procedure | 
| Patients' characteristics | To describe accurately patients' characteristics in terms of demographics | At the date of the diagnostic procedure | 
| Patients' characteristics | To describe accurately patients' characteristics in type of tumor | At the date of the diagnostic procedure | 
| Patients' characteristics | To describe accurately patients' characteristics in type of anticancer treatment, | At the date of the diagnostic procedure | 
| Patients' characteristics | To describe accurately patients' characteristics in terms of comorbidities | At the date of the diagnostic procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Oncology, Epidemiology, Predictive factors